Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Jan 6;16(1):1209-20.
doi: 10.3390/ijms16011209.

Analgesic, anxiolytic and anaesthetic effects of melatonin: new potential uses in pediatrics

Lucia Marseglia  1 , Gabriella D'Angelo  2 , Sara Manti  3 , Salvatore Aversa  4 , Teresa Arrigo  5 , Russel J Reiter  6 , Eloisa Gitto  7
Affiliations
Review

Analgesic, anxiolytic and anaesthetic effects of melatonin: new potential uses in pediatrics

Lucia Marseglia et al. Int J Mol Sci. .

Abstract

Exogenous melatonin is used in a number of situations, first and foremost in the treatment of sleep disorders and jet leg. However, the hypnotic, antinociceptive, and anticonvulsant properties of melatonin endow this neurohormone with the profile of a drug that modulates effects of anesthetic agents, supporting its potential use at different stages during anesthetic procedures, in both adults and children. In light of these properties, melatonin has been administered to children undergoing diagnostic procedures requiring sedation or general anesthesia, such as magnetic resonance imaging, auditory brainstem response tests and electroencephalogram. Controversial data support the use of melatonin as anxiolytic and antinociceptive agents in pediatric patients undergoing surgery. The aim of this review was to evaluate available evidence relating to efficacy and safety of melatonin as an analgesic and as a sedative agent in children. Melatonin and its analogs may have a role in antinociceptive therapies and as an alternative to midazolam in premedication of adults and children, although its effectiveness is still controversial and available data are clearly incomplete.

PubMed Disclaimer

References

    1. Gitto E., Marseglia L., Manti S., D’Angelo G., Barberi I., Salpietro C., Reiter R.J. Protective role of melatonin in neonatal diseases. Oxid. Med. Cell. Longev. 2013 doi: 10.1155/2013/980374. - DOI - PMC - PubMed
    1. Ross C., Davies P., Whitehouse W. Melatonin treatment for sleep disorders in children with neurodevelopmental disorders: An observational study. Dev. Med. Child Neurol. 2002;44:339–344. doi: 10.1111/j.1469-8749.2002.tb00821.x. - DOI - PubMed
    1. Hardeland R., Poeggeler B. Melatonin beyond its classical functions. Open Physiol. J. 2008;1:1–23. doi: 10.2174/1874360900901010001. - DOI
    1. Golombek D.A., Escolar E., Burin L.J., de Brito Sánchez M.G., Fernández Duque D., Cardinali D.P. Chronopharmacology of melatonin: Inhibition by benzodiazepine antagonism. Chronobiol. Int. 1992;9:124–131. doi: 10.3109/07420529209064523. - DOI - PubMed
    1. Golombek D.A., Pévet P., Cardinali D.P. Melatonin effects on behavior: Possible mediation by the central GABAergic system. Neurosci. Biobehav. Rev. 1996;20:403–412. doi: 10.1016/0149-7634(95)00052-6. - DOI - PubMed

LinkOut - more resources